查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433658

病毒載體/質體DNA 製造市場規模、佔有率和趨勢分析報告：按載體類型、工作流程、應用、最終用途、疾病、地區和細分市場進行預測，2024-2030 年

Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End-use, By Disease, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

病毒載體和質體DNA 製造市場的成長和趨勢：

Grand View Research, Inc.最新報告預測，到2030年，全球病毒載體和質體DNA製造市場規模預計將達到195億美元，2024年至2030年複合年成長率為20.2%。

隨著基因療法對質體DNA 和病毒載體的需求增加，產業領導者正在引入新技術來提高質體DNA 的生產。例如，2018年4月，GE醫療生命科學宣布推出KUBio BSL 2，這是一種預製模組化生物加工設施，用於生產基於病毒載體的溶瘤病毒、細胞和基因治療以及免疫學。

隨著細胞和基因治療研究領域的投資增加，市場對病毒載體的需求空前。因此，各個組織正在提供資金來加速這些載體的製造流程的發展。例如，2019年9月，加拿大下一代製造公司向iVexSol Canada主導的聯盟提供了189萬美元。這筆資金用於開發慢病毒載體的先進製造流程。 2iVexSol Canada 是一家向量製造公司，與多家公司合作開發先進的 LVV 製造平台。

此外，在這個市場上營運的主要企業，包括 Thermo Fisher Scientific、QIAGEN NV、Agilent Technologies、Takara Bio 和 Oxford Biomedica，都專注於開發新的基因轉移平台。這些公司正在進行大量投資，擴大生物基因轉移系統的生產，以滿足不斷成長的市場需求。例如，2020年5月，Takara Bio在滋賀縣完成了基因和細胞治療處理II中心（CGCPII）的建造。該中心是該公司 GMP 病毒載體生產設施的補充。同樣，賽默飛世爾科技於 2020 年 5 月投資 1.8 億美元，將其病毒載體生產能力提高了一倍。預計此類舉措的增加將在預測期內推動市場成長。

此外，病毒載體的大規模生產面臨上游工程的挑戰。在上游工程中，生產病毒載體的方法是製造商的主要障礙之一。大規模複製貼壁細胞培養是一個需要解決的重要問題。因此，研究人員正在嘗試使用大型反應器來培養這些細胞。此外，需要更了解下游加工中這些載體的純度。

病毒載體和質體DNA 製造市場報告亮點：

  • 根據載體類型，由於高需求和臨床試驗中使用量的增加，腺結合病毒(AAV) 細分市場在 2023 年佔據市場主導地位，銷售佔有率為 20.0%。
  • 基於工作流程，下游處理領域在工作流程領域中佔據最大的收益佔有率，並由於下游處理技術的進步和一次性系統的採用而在2023年引領市場。
  • 從應用來看，疫苗治療領域預計將在 2023 年以最大的收益佔有率主導市場，而細胞治療預計在預測期內將以最快的複合年成長率成長。
  • 以最終用途分類，研究機構細分市場佔據主導地位，到 2023 年收益佔有率最大。另一方面，製藥和生物製藥公司預計在預測期內將以最快的複合年成長率成長。
  • 按疾病分類，腫瘤領域預計將在 2023 年以最大的收益佔有率主導市場，並在預測期內以最快的複合年成長率成長。
  • 北美由於癌症和感染疾病負擔高、購買力平價高、政府對優質醫療保健的支持以及可報銷等因素在市場上佔據主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 病毒載體和質體DNA 製造市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 病毒載體/質體DNA製造市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第 4 章 病毒載體/質體DNA 製造市場：載體類型估計與趨勢分析

  • 按載體類型分類的全球病毒載體和質體DNA 製造市場前景
  • 腺結合病毒（AAV）
  • 慢病毒
  • 腺病毒
  • 逆轉錄病毒
  • 質體
  • 其他

第5章病毒載體/質體DNA製造市場：工作流程估計與趨勢分析

  • 按工作流程分類的全球病毒載體和質體DNA 製造市場前景
  • 上游加工
  • 下游加工

第6章 病毒載體/質體DNA製造市場：使用量估算與趨勢分析

  • 全球病毒載體與質體DNA製造市場（依應用）展望
  • 基因治療
  • 細胞療法
  • 疫苗
  • 研究用途

第 7 章 病毒載體/質體DNA 製造市場：最終用途估計與趨勢分析

  • 按最終用途分類的全球病毒載體和質體DNA 製造市場前景
  • 製藥公司/生物製藥公司
  • 研究機構

第8章病毒載體/質體DNA製造市場：疾病估計與趨勢分析

  • 按疾病分類的全球病毒載體和質體DNA 製造市場展望
  • 癌症
  • 遺傳疾病
  • 感染疾病
  • 其他

第9章病毒載體/質體DNA製造市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章競爭形勢

  • 公司分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/名單
    • Merck KGaA
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Thermo Fisher Scientific
    • Cobra Biologics
    • Catalent Inc.
    • Wuxi Biologics
    • Takara Bio Inc.
    • Waisman Biomanufacturing
    • Genezen laboratories
    • Batavia Biosciences
    • Miltenyi Biotec GmbH
    • SIRION Biotech GmbH
    • Virovek Incorporation
    • BioNTech IMFS GmbH
    • Audentes Therapeutics
    • BioMarin Pharmaceutical
    • RegenxBio, Inc.
Product Code: GVR-2-68038-695-0

Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends:

The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.

With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.

Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.

Viral Vector And Plasmid DNA Manufacturing Market Report Highlights:

  • Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
  • Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
  • Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
  • Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
  • In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
  • North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vector type
    • 1.2.2. Workflow
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Disease
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
      • 3.2.1.2. Technological Advancements in Manufacturing Vectors
      • 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
  • 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis

  • 4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
  • 4.2. Adeno-associated virus (AAV)
    • 4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.3. Lentivirus
    • 4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.4. Adenovirus
    • 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5. Retrovirus
    • 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.6. Plasmids
    • 4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis

  • 5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
  • 5.2. Upstream Manufacturing
    • 5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.2.2. Vector Amplification & Expansion
      • 5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.2.3. Vector Recovery/Harvesting
      • 5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.3. Downstream Manufacturing
    • 5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.3.2. Purification
      • 5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
    • 5.3.3. Fill Finish diagnostic instruments
      • 5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis

  • 6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
  • 6.2. Gene Therapy
    • 6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.3. Cell Therapy
    • 6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4. Vaccinology
    • 6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5. Research Applications
    • 6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis

  • 7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
  • 7.2. Pharmaceutical and Biopharmaceutical Companies
    • 7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.3. Research Institutes
    • 7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis

  • 8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
  • 8.2. Cancer
    • 8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.3. Genetic Disorders
    • 8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4. Infectious Diseases
    • 8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5. Other
    • 8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. North America
    • 9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key country dynamics
      • 9.2.2.2. Regulatory framework
      • 9.2.2.3. Competitive scenario
      • 9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.2.2.5. Target disease prevalence
    • 9.2.3. Canada
      • 9.2.3.1. Key country dynamics
      • 9.2.3.2. Regulatory framework
      • 9.2.3.3. Competitive scenario
      • 9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.2.3.5. Target disease prevalence
  • 9.3. Europe
    • 9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.2.5. Target disease prevalence
    • 9.3.3. Germany
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.3.5. Target disease prevalence
    • 9.3.4. France
      • 9.3.4.1. Key country dynamics
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive scenario
      • 9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.4.5. Target disease prevalence
    • 9.3.5. Italy
      • 9.3.5.1. Key country dynamics
      • 9.3.5.2. Regulatory framework
      • 9.3.5.3. Competitive scenario
      • 9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.5.5. Target disease prevalence
    • 9.3.6. Spain
      • 9.3.6.1. Key country dynamics
      • 9.3.6.2. Regulatory framework
      • 9.3.6.3. Competitive scenario
      • 9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.6.5. Target disease prevalence
    • 9.3.7. Norway
      • 9.3.7.1. Key country dynamics
      • 9.3.7.2. Regulatory framework
      • 9.3.7.3. Competitive scenario
      • 9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.7.5. Target disease prevalence
    • 9.3.8. Sweden
      • 9.3.8.1. Key country dynamics
      • 9.3.8.2. Regulatory framework
      • 9.3.8.3. Competitive scenario
      • 9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.8.5. Target disease prevalence
    • 9.3.9. Denmark
      • 9.3.9.1. Key country dynamics
      • 9.3.9.2. Regulatory framework
      • 9.3.9.3. Competitive scenario
      • 9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.3.9.5. Target disease prevalence
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.2.5. Target disease prevalence
    • 9.4.3. China
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.3.5. Target disease prevalence
    • 9.4.4. India
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.4.5. Target disease prevalence
    • 9.4.5. Australia
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.5.5. Target disease prevalence
    • 9.4.6. South Korea
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.6.5. Target disease prevalence
    • 9.4.7. Thailand
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.4.7.5. Target disease prevalence
  • 9.5. Latin America
    • 9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.5.2.5. Target disease prevalence
    • 9.5.3. Mexico
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.5.3.5. Target disease prevalence
    • 9.5.4. Argentina
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.5.4.5. Target disease prevalence
  • 9.6. MEA
    • 9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.2.5. Target disease prevalence
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.3.5. Target disease prevalence
    • 9.6.4. UAE
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.4.5. Target disease prevalence
    • 9.6.5. Kuwait
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
      • 9.6.5.5. Target disease prevalence

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Position Analysis, 2023
  • 10.4. Company Profiles/Listing
    • 10.4.1. Merck KGaA
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Lonza
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. FUJIFILM Diosynth Biotechnologies
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Thermo Fisher Scientific
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Cobra Biologics
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. Catalent Inc.
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. Wuxi Biologics
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives
    • 10.4.8. Takara Bio Inc.
      • 10.4.8.1. Company overview
      • 10.4.8.2. Financial performance
      • 10.4.8.3. Product benchmarking
      • 10.4.8.4. Strategic initiatives
    • 10.4.9. Waisman Biomanufacturing
      • 10.4.9.1. Company overview
      • 10.4.9.2. Financial performance
      • 10.4.9.3. Product benchmarking
      • 10.4.9.4. Strategic initiatives
    • 10.4.10. Genezen laboratories
      • 10.4.10.1. Company overview
      • 10.4.10.2. Financial performance
      • 10.4.10.3. Product benchmarking
      • 10.4.10.4. Strategic initiatives
    • 10.4.11. Batavia Biosciences
      • 10.4.11.1. Company overview
      • 10.4.11.2. Financial performance
      • 10.4.11.3. Product benchmarking
      • 10.4.11.4. Strategic initiatives
    • 10.4.12. Miltenyi Biotec GmbH
      • 10.4.12.1. Company overview
      • 10.4.12.2. Financial performance
      • 10.4.12.3. Product benchmarking
      • 10.4.12.4. Strategic initiatives
    • 10.4.13. SIRION Biotech GmbH
      • 10.4.13.1. Company overview
      • 10.4.13.2. Financial performance
      • 10.4.13.3. Product benchmarking
      • 10.4.13.4. Strategic initiatives
    • 10.4.14. Virovek Incorporation
      • 10.4.14.1. Company overview
      • 10.4.14.2. Financial performance
      • 10.4.14.3. Product benchmarking
      • 10.4.14.4. Strategic initiatives
    • 10.4.15. BioNTech IMFS GmbH
      • 10.4.15.1. Company overview
      • 10.4.15.2. Financial performance
      • 10.4.15.3. Product benchmarking
      • 10.4.15.4. Strategic initiatives
    • 10.4.16. Audentes Therapeutics
      • 10.4.16.1. Company overview
      • 10.4.16.2. Financial performance
      • 10.4.16.3. Product benchmarking
      • 10.4.16.4. Strategic initiatives
    • 10.4.17. BioMarin Pharmaceutical
      • 10.4.17.1. Company overview
      • 10.4.17.2. Financial performance
      • 10.4.17.3. Product benchmarking
      • 10.4.17.4. Strategic initiatives
    • 10.4.18. RegenxBio, Inc.
      • 10.4.18.1. Company overview
      • 10.4.18.2. Financial performance
      • 10.4.18.3. Product benchmarking
      • 10.4.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 18 Europe viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 19 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 20 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 21 Europe viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Europe viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 24 UK viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 25 UK viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 26 UK viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 27 UK viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 UK viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 30 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 31 Germany viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 32 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Germany viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 34 France viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 35 France viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 36 France viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 37 France viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 France viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 39 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 40 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 41 Spain viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 42 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Spain viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 44 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 45 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 46 Italy viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 47 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Italy viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 49 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 50 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 51 Denmark viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 52 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 55 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 56 Sweden viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 57 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 59 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 60 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 61 Norway viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 62 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 Norway viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 70 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 71 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 72 Japan viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 73 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 Japan viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 75 China viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 76 China viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 77 China viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 78 China viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 China viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 80 India viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 81 India viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 82 India viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 83 India viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 India viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 85 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 86 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 87 South Korea viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 88 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 90 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 91 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 92 Australia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 93 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 94 Australia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 95 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 96 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 97 Thailand viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 98 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 99 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 100 Latin America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 101 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 102 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 103 Latin America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 104 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 105 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 106 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 107 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 108 Brazil viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 109 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 110 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 111 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 112 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 113 Mexico viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 114 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 115 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
  • Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
  • Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
  • Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
  • Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
  • Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Viral vector and plasmid DNA manufacturing market driver impact
  • Fig. 15 Viral vector and plasmid DNA manufacturing market restraint impact
  • Fig. 16 Viral vector and plasmid DNA manufacturing market strategic initiatives analysis
  • Fig. 17 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
  • Fig. 18 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
  • Fig. 19 Adenovirus market estimates and forecast, 2018 - 2030
  • Fig. 20 Retrovirus market estimates and forecast, 2018 - 2030
  • Fig. 21 Adeno-Associated Virus (AAV)market estimates and forecast, 2018 - 2030
  • Fig. 22 Lentivirus market estimates and forecast, 2018 - 2030
  • Fig. 23 Plasmids market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 Viral vector and plasmid DNA manufacturing market: Workflow movement Analysis
  • Fig. 26 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
  • Fig. 27 Upstream manufacturing market estimates and forecasts, 2018 - 2030
  • Fig. 28 Vector amplification & expansion market estimates and forecasts, 2018 - 2030
  • Fig. 29 Vector recovery/harvesting market estimates and forecasts, 2018 - 2030
  • Fig. 30 Downstream manufacturing market estimates and forecasts, 2018 - 2030
  • Fig. 31 Purification market estimates and forecasts, 2018 - 2030
  • Fig. 32 Fill finish market estimates and forecasts, 2018 - 2030
  • Fig. 33 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
  • Fig. 34 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
  • Fig. 35 Antisense & RNAi therapy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Gene Therapy market estimates and forecasts, 2018 - 2030
  • Fig. 37 Cell Therapy market estimates and forecasts, 2018 - 2030
  • Fig. 38 Vaccinology market estimates and forecasts, 2018 - 2030
  • Fig. 39 Research Applications market estimates and forecasts, 2018 - 2030
  • Fig. 40 Viral vector and plasmid DNA manufacturing market: End-use movement Analysis
  • Fig. 41 Viral vector and plasmid DNA manufacturing market: End-use outlook and key takeaways
  • Fig. 42 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2018 - 2030
  • Fig. 43 Research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 44 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
  • Fig. 45 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
  • Fig. 46 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 47 Genetic disorders market estimates and forecasts, 2018 - 2030
  • Fig. 48 Infectious Diseases market estimates and forecasts, 2018 - 2030
  • Fig. 49 Others market estimates and forecasts, 2018 - 2030
  • Fig. 50 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
  • Fig. 51 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
  • Fig. 52 Global viral vector and plasmid DNA manufacturing market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America
  • Fig. 55 North America market estimates and forecasts, 2018 - 2030
  • Fig. 56 U.S.
  • Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 58 Canada
  • Fig. 59 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 60 Europe
  • Fig. 61 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 62 UK
  • Fig. 63 UK market estimates and forecasts, 2018 - 2030
  • Fig. 64 Germany
  • Fig. 65 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 66 France
  • Fig. 67 France market estimates and forecasts, 2018 - 2030
  • Fig. 68 Italy
  • Fig. 69 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 70 Spain
  • Fig. 71 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 72 Denmark
  • Fig. 73 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 74 Sweden
  • Fig. 75 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 76 Norway
  • Fig. 77 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 78 Asia Pacific
  • Fig. 79 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 80 China
  • Fig. 81 China market estimates and forecasts, 2018 - 2030
  • Fig. 82 Japan
  • Fig. 83 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 84 India
  • Fig. 85 India market estimates and forecasts, 2018 - 2030
  • Fig. 86 Thailand
  • Fig. 87 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 88 South Korea
  • Fig. 89 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 90 Australia
  • Fig. 91 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 92 Latin America
  • Fig. 93 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 94 Brazil
  • Fig. 95 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 96 Mexico
  • Fig. 97 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 98 Argentina
  • Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 100 Middle East and Africa
  • Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 102 South Africa
  • Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 Saudi Arabia
  • Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 106 UAE
  • Fig. 107 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 108 Kuwait
  • Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 110 Market share of key market players- Viral vector and plasmid DNA manufacturing market